Back to Search Start Over

Antibodies as biomarker candidates for response and survival to checkpoint inhibitors in melanoma patients

Authors :
Mirjam Fässler
Stefan Diem
Joanna Mangana
Omar Hasan Ali
Fiamma Berner
David Bomze
Sandra Ring
Rebekka Niederer
Cristina del Carmen Gil Cruz
Christian Ivan Pérez Shibayama
Michal Krolik
Marco Siano
Markus Joerger
Mike Recher
Lorenz Risch
Sabine Güsewell
Martin Risch
Daniel E. Speiser
Burkhard Ludewig
Mitchell P. Levesque
Reinhard Dummer
Lukas Flatz
Source :
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-12 (2019)
Publication Year :
2019
Publisher :
BMJ Publishing Group, 2019.

Abstract

Abstract Background Long-term survival of stage IV melanoma patients has improved significantly with the development of immune checkpoint inhibitors (CIs). Reliable biomarkers to predict response and clinical outcome are needed. Methods We investigated the role of melanoma-associated antibodies as predictive markers for CI therapy in two independent cohorts. In cohort 1, a prospective study, we measured specific antibodies before treatment, after one week and after six to nine weeks of treatment. Cohort 2 consisted of serum samples prior to CI therapy initiation. ELISA assays were performed to quantify specific IgG directed against melanocyte differentiation antigens tyrosinase-related proteins 1 and 2 (TRP1/TYRP1 and TRP2/TYRP2), glycoprotein 100 (gp100), MelanA/MART1, and the cancer-testis antigen NY-ESO-1. Response was defined as either complete or partial remission on CT scan according to RECIST 1.1. Results In cohort 1, baseline levels of these antibodies were higher in the responder group, although statistical significance was only reached for NY-ESO-1 (p = 0.007). In cohort 2, significantly higher antibody baseline levels for MelanA/MART1 (p = 0.003) and gp100 (p = 0.029) were found. After pooling the results from both cohorts, higher levels of MelanA/MART1 (p = 0.013), TRP1/TYRP1 (p = 0.048), TRP2/TYRP2 (p = 0.047) and NY-ESO-1 (p = 0.005) specific antibodies at baseline were independently associated with response. Conclusions Melanoma-associated antibodies may be candidate biomarkers for response and survival in metastatic melanoma patients being treated with CIs. These markers may be used to complement patient assessment, in combination with PD-L1 status, tumor-infiltrating lymphocytes and tumor mutational burden, with the aim to predict outcome of CI treatment in patients with metastatic melanoma. Trial registration Ethikkommission Ostschweiz, EKOS 16/079 https://ongoingprojects.swissethics.ch/runningProjects_list.php?q=%28BASECID~contains~2016-00998%29&orderby=dBASECID.

Details

Language :
English
ISSN :
20511426
Volume :
7
Issue :
1
Database :
Directory of Open Access Journals
Journal :
Journal for ImmunoTherapy of Cancer
Publication Type :
Academic Journal
Accession number :
edsdoj.1538a3adc5e74af7bbb8b700ef2dbd95
Document Type :
article
Full Text :
https://doi.org/10.1186/s40425-019-0523-2